drugset / Trial / NCT00755703
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
RandomizedFactorialQuadruple-blindPrevention
Summary
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in preclinical studies. The vaccine is non-replicating, tissue culture based and designed for intranasal delivery.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-09
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pandemic Influenza Vaccine | Vaccine | 1e+08 unknown | Intranasal |
| Subject | Pandemic Influenza Vaccine | Vaccine | 1e+09 unknown | Intranasal |
| Subject | Pandemic Influenza Vaccine | Vaccine | 1e+10 unknown | Intranasal |